Equashield 1

Equashield

Hazardous Drug Compounding Technologies

Equashield is a leading global provider of closed system transfer devices (CSTDs) designed to protect healthcare professionals from exposure to hazardous drugs.

With a relentless focus on quality, safety, and ease of use, Equashield’s product offerings are based on proprietary technologies spanning both manual CSTDs and novel automated compounding solutions – including a next-generation automated compounding system utilising artificial intelligence to deliver superior performance.

Company Background

  • Since its founding in 2009, Equashield has recorded robust growth fuelled by continued product innovation, high customer satisfaction, and the pioneering of new technological solutions for handling hazardous drugs.
  • Products are sold across five continents Equashield is a leading CSTD provider in the largest global market, the US.

Vision & Outlook

  • Opportunity to leverage its technological edge to further accelerate growth.
  • Pipeline of innovative compounding technologies, including a novel automated drug compounding system.
  • Vast potential of compounding automation to improve safety and efficiency in the handling of hazardous drugs.
EQ Logo CMYK 2021 2

SECTOR

Healthcare

REVENUES 2023

EUR 110 million

EMPLOYEES

460

OWNERSHIP

Fund XI

INVESTMENT DATE

2022

HEAD OFFICE

Tefen, Israel

MANAGEMENT

Eric Shem-Tov

CEO

Itamar Petersil

CFO

RESPONSIBLE ADVISOR

Joel Davidkin

Partner

Nordic Capital's healthcare focus

Nordic Capital is one of the most active and experienced investors in healthcare globally, focusing on investments in companies throughout the healthcare space with potential to grow and expand into new markets and industry-leading innovations or value propositions.

Learn more here: